Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland
DOI:
https://doi.org/10.56782/pps.134Keywords:
SMA, nusinersen, risdiplam, zolgensmaAbstract
Spinal muscular atrophy (SMA) is a rare hereditary neuromuscular disorder caused by a genetic mutation in the Survival of motor neuron 1 (SMN1) gene, which is responsible for the production of a protein essential to motor neurons’ survival. Insufficient levels of the SMN protein lead to the loss of motor neurons in the spinal cord, which manifests in progressive muscle wasting. Due to the absence of an effective treatment in the early years, the disease was taking its toll with the respiratory problems being the primary cause of death. Currently, there are multiple approved treatments for SMA, which help to manage the symptoms and to prevent complications, such as nusinersen, risdiplam, and onasemnogene abeparvovec. In Poland, nusinersen treatment has been offered free of charge by the public health service since 2019. It was not until September 2022 that the reimbursement procedure included the other two drugs. The recently published studies on the nusinersen treatment in Poland showed stabilization or slowdown in the progression of symptoms in all patients. In March 2022, Poland implemented an SMA screening program for newborns, which aimed to detect this fatal and disabling disease before the infant displayed any SMA symptoms. The program resulted so far in early diagnosis and intervention providing a better prognosis for patients. Combination of newborn screening and the drug reimbursement program has significantly increased the chances of SMA patients for effective treatment.
Downloads
References
Vill, K., et al., One Year of Newborn Screening for SMA - Results of a German Pilot Project. J. Neuromuscul Dis, 2019. 6(4): p. 503-515. doi: 10.3233/jnd-190428 DOI: https://doi.org/10.3233/JND-190428
Jedrzejowska, M., et al., Incidence of spinal muscular atrophy in Poland--more frequent than predicted? Neuroepidemiology, 2010. 34(3): p. 152-7. doi: 10.1159/000275492 DOI: https://doi.org/10.1159/000275492
Lusakowska, A., et al., Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy. Orphanet J Rare Dis, 2021, 16(1), Art. No: 150, doi: 10.1186/s13023-021-01771-y DOI: https://doi.org/10.1186/s13023-021-01771-y
Kotulska-Jóźwiak, K, K.-P.A., Mazurkiewicz-Bełdzińska, M. et al., Rdzeniowy zanik mięśni (SMA). Leczenie SMA w Polsce. Nowa jakość pacjentów i opiekunów ISBN:978-83-962944-5-6. 2022: Warszawa.
Jedrzejowska, M., et al., Unaffected patients with a homozygous absence of the SMN1 gene. Eur J Hum Genet, 2008. 16(8): p. 930-4., doi: 10.1038/ejhg.2008.41 DOI: https://doi.org/10.1038/ejhg.2008.41
Wirth, B., et al., Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet, 2006. 119(4): p. 422-8., doi: 10.1007/s00439-006-0156-7 DOI: https://doi.org/10.1007/s00439-006-0156-7
Kolb, S.J., et al., Natural history of infantile-onset spinal muscular atrophy. Ann Neurol, 2017. 82(6): p. 883-891, doi: 10.1002/ana.25101 DOI: https://doi.org/10.1002/ana.25101
Lejman, J., et al., Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives. Int J Mol Sci, 2023. 24(2) Art. No:1130, doi: 10.3390/ijms24021130 DOI: https://doi.org/10.3390/ijms24021130
Finkel, R., et al., Efficacy and safety of nusinersen in infants with spinal muscular atrophy (SMA): final results from the phase 3 ENDEAR study. Eur. J. Paediatr. Neurol., 2017. 21: p. e14-e15, doi: 10.1016/j.ejpn.2017.04.1219 DOI: https://doi.org/10.1016/j.ejpn.2017.04.1219
Abreu, N.J. and M.A. Waldrop, Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol, 2021. 56(4): p. 710-720, doi: 10.1002/ppul.25055 DOI: https://doi.org/10.1002/ppul.25055
Baranello, G., et al., Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med, 2021. 384(10): p. 915-923, doi: 10.1056/NEJMoa2009965 DOI: https://doi.org/10.1056/NEJMoa2009965
Dhillon, S., Risdiplam: First Approval. Drugs, 2020. 80(17): p. 1853-1858, doi: 10.1007/s40265-020-01410-z DOI: https://doi.org/10.1007/s40265-020-01410-z
FDA. CDER Highlights of Prescribing Information: EVRYSDI (Risdisplam) [cited 2023 24.02.2023]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213535s003s005lbl.pdf.
Ravi, B., et al., Genetic approaches to the treatment of inherited neuromuscular diseases. Hum Mol Genet, 2019. 28(R1): p. R55-r64, doi: 10.1093/hmg/ddz131 DOI: https://doi.org/10.1093/hmg/ddz131
Poirier, A., et al., Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect, 2018. 6(6): Art. No: e00447, doi: 10.1002/prp2.447 DOI: https://doi.org/10.1002/prp2.447
Waldrop, M.A. and S.J. Kolb, Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol, 2019. 21(6): Art.No: 25, doi: 10.1007/s11940-019-0568-z DOI: https://doi.org/10.1007/s11940-019-0568-z
Majchrzak-Celińska, A.A., A. Warych, and M. Szoszkiewicz, Rdzeniowy zanik mięśni–onasemnogene abeparvovec i inne opcje terapeutyczne. Farmacja Polska, 2020. 76(1): p. 10-17, doi: 10.32383/farmpol/118343 DOI: https://doi.org/10.32383/farmpol/118343
Jączak-Goździak, M. and B. Steinborn, Terapie genowe i genetyczne w chorobach nerwowo-mięśniowych wieku dziecięcego. Neurologia Dziecięca, 2020. 29(58): p. 11-18, doi: 10.20966/chn.2020.58.453 DOI: https://doi.org/10.20966/chn.2020.58.453
Załącznik B.102 Leczenie Rdzeniowego Zaniku Mięśni. [cited 2023 24.02]; Available from: https://www.gov.pl/attachment/7feb6c24-b7f6-4a76-b87b-8064308b6495.
Kotulska, K., et al., Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy. Eur J Paediatr Neurol, 2022. 39: p. 103-109, doi: 10.1016/j.ejpn.2022.06.001 DOI: https://doi.org/10.1016/j.ejpn.2022.06.001
Finkel, R.S., et al., Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med, 2017. 377(18): p. 1723-1732, doi: 10.1056/NEJMoa1702752 DOI: https://doi.org/10.1056/NEJMoa1702752
Vill, K., et al., Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis, 2021. 16(1): Art.No: 153, doi: 10.1186/s13023-021-01783-8 DOI: https://doi.org/10.1186/s13023-021-01783-8
De Vivo, D.C., et al., Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord, 2019. 29(11): p. 842-856, doi: 10.1016/j.nmd.2019.09.007 DOI: https://doi.org/10.1016/j.nmd.2019.09.007
Finkel, R.S., et al., Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology, 2014. 83(9): p. 810-7, doi: 10.1212/wnl.0000000000000741 DOI: https://doi.org/10.1212/WNL.0000000000000741
Hale, J.E., et al., Massachusetts' Findings from Statewide Newborn Screening for Spinal Muscular Atrophy. Int J Neonatal Screen, 2021. 7(2), doi: 10.3390/ijns7020026 DOI: https://doi.org/10.3390/ijns7020026
Strauss, K.A., et al., Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med, 2022. 28(7): p. 1390-1397, doi: 10.1038/s41591-022-01867-3 DOI: https://doi.org/10.1038/s41591-022-01867-3
Przedłużenie Rządowego programu badań przesiewowych w Polsce na lata 2023-2026 [accessed 2023 24.02]; Available from: https://www.gov.pl/attachment/1b5df5d8-58e0-4eea-95fc-8f45fb58914d
Ołtarzewski, M. Badania przesiewowe noworodków w Polsce, 2018 rok. Postępy Neonatologii, 2018. 24(2) p:111-122, doi: 10.31350/postepyneonatologii/2018/2/ DOI: https://doi.org/10.31350/postepyneonatologii/2018/2/PN2018025
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
